Metastatic
-
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Phase 2 · randomised · 120 people · 9 sites in United States · Recruiting now
-
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
Phase 3 · randomised · 80 people · 19 sites in China · Recruiting now
-
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Phase 2 · randomised · 110 people · 3 sites in 2 countries · Recruiting now
-
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Phase 3 · randomised · 400 people · 3 sites in United States · Recruiting now
-
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Phase 2 · randomised · 150 people · 5 sites in 3 countries · Recruiting now
-
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Phase 3 · randomised · 430 people · 1 site in China · Recruiting now
-
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Phase 3 · randomised · 560 people · 2 sites in China · Recruiting now
-
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Phase 3 · randomised · 280 people · 1 site in China · Recruiting now
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Phase 2 · 60 people · 1 site in United States · Recruiting now
-
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers
Phase 2 · 220 people · 55 sites in 13 countries · Recruiting now